Thyrotropin secreting pituitary adenoma: a clinical case of postoperative re-onset thyrotoxicosis with adenoma recurrence
  • Ariana Maia
    Division of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de Santo António
  • Catarina Cidade Rodrigues
    Division of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Tâmega e Sousa
  • Isabel Ribeiro
    Neurosurgery Division, Centro Hospitalar Universitário de Santo António
  • Cláudia Amaral
    Division of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de Santo António

Keywords

pituitary adenoma, thyrotoxicosis, hyperthyroidism, thyrotropin, neurosurgery

Abstract

We report a case of a 19-year-old young male presenting with thyrotoxicosis with inappropriately elevated TSH. Magnetic resonance imaging revealed a pituitary adenoma (8.2 x 9.7 mm), TRH stimulation test showed abnormal blunted TSH response, and serum glycoprotein hormone alpha-sub-unit was elevated. He had no family history of thyroid disease and TR-beta genetic testing excluded resistance to thyroid hormone action. The diagnosis of thyrotropin-secreting pituitary adenoma (TSHoma) was presumed and long-acting somatostatin analogue was promptly initiated. After two months of octreotide treatment, serum TSH and FT3 returned to within normal ranges. Tumour resection by transsphenoidal surgery was performed and, ten days after surgery, clinical hypothyroidism was achieved, despite detectable TSH levels (TSH 1.02 µU/ml[RR 0.27-4.2]). Although the patient remained euthyroid for the following three years, there was a gradual biochemical elevation in the levels of TSH, FT4, and FT3 over time, reaching serum values above the normal limit in the third year after surgery. Imaging did not show neoplasm recurrence at this point. After two years, the patient presented with clinical manifestations of re-onset thyrotoxicosis, with MRI revealing a T2 hypersignal oval area compatible with a pituitary adenoma. Adenectomy was performed. Histopathological and immunohistochemical analyses revealed a pituitary adenoma with transcription factor PIT1 expression and positivity for TSH and PRL. TSHoma treatment may not be always effective in the first therapeutic approach and recurrences are a possibility, making follow-up essential. The present case highlights the heterogeneity of post-treatment cure criteria and their limitations.

VIEW THE ENTIRE ARTICLE

References

  • Cossu G, Daniel RT, Pierzchala K, Berhouma M, Pitteloud N, Lamine F, et al. Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management. Pituitary 2019;22:79-88.
  • Tjörnstrand A, Nyström HF. Diagnosis of endocrine disease: Diagnostic approach to TSH-producing pituitary adenoma. Eur J Endocrinol 2017;177:R183-r97.
  • Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2013;2:76-82.
  • Beck-Peccoz P, Giavoli C, Lania A. A 2019 update on TSH-secreting pituitary adenomas. J Endocrinol Invest 2019;42:1401-6.
  • Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996;81:3084-90.
  • Views: 378
    HTML downloads: 72
    PDF downloads: 358


    Published: 2023-05-15
    Issue: 2023: Vol 10 No 6 (view)


    How to cite:
    1.
    Maia A, Cidade Rodrigues C, Ribeiro I, Amaral C. Thyrotropin secreting pituitary adenoma: a clinical case of postoperative re-onset thyrotoxicosis with adenoma recurrence. EJCRIM 2023;10 doi:10.12890/2023_003905.

    Similar Articles

    You may also start an advanced similarity search for this article.